Imagion Biosystems announces the presentation “MagSense® Imaging: Early Detection of Cancer Through Targeted Imaging.”
See the presentation “MagSense® Imaging“.
Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited